Detecting latent tuberculosis infection during anti-tumour necrosis factor therapy
There is little information regarding the reliability of repeat tuberculin skin tests (TSTs) and interferon gamma release assays (IGRAs) in detecting latent tuberculosis infection (LTBI) in people on anti-tumour necrosis factor (TNF) medication. We conducted a prospective, observational study of pat...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental rheumatology 2011-09, Vol.29 (5), p.790-794 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 794 |
|---|---|
| container_issue | 5 |
| container_start_page | 790 |
| container_title | Clinical and experimental rheumatology |
| container_volume | 29 |
| creator | RINGROSE, J. S SANCHE, S. E TAYLOR-GJEVRE, R. M |
| description | There is little information regarding the reliability of repeat tuberculin skin tests (TSTs) and interferon gamma release assays (IGRAs) in detecting latent tuberculosis infection (LTBI) in people on anti-tumour necrosis factor (TNF) medication.
We conducted a prospective, observational study of patients referred to the Saskatoon Tuberculosis (TB) Clinic prior to starting anti-TNF medication. A chest x-ray (CXR), 2-step TST and IGRA (QuantiFERON-TB Gold In-Tube Method) were performed at baseline. Those patients with a baseline TST ≥10 mm and/or a positive IGRA were followed with a clinic visit, CXR, TST and IGRA at 3 and 6 months after starting anti-TNF medication.
Of 106 potential patients, 91 consented to participate. Twenty-six patients had a positive (≥ 10 mm) TST or IGRA at baseline; twelve started and stayed on anti-TNF medication through the 6-month follow-up and completed both planned follow-up visits. The baseline mean TST measurement for the 12 participants was 13.9 mm (SD 11.4), increasing to a mean of 16.8 mm (SD 9.3) post-booster. At 3 months post-anti-TNF initiation, there was an overall decrease in TST measurement (mean=10.0 mm; SD 9.3; p=0.013), with measurements |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_901641921</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>901641921</sourcerecordid><originalsourceid>FETCH-LOGICAL-p240t-29aca5bc7c78d1d980bffc3fcc8ef9618367562d725ef232f5c07d7ac5e705983</originalsourceid><addsrcrecordid>eNpF0EtLAzEUBeAgiq3VvyCzEVcDeTSvpdQnFARR6G7I3Ek0MpMZ81j039tqxdVdnI_D4R6hOeGa1VirzTGaY6ZprbjYzNBZSp8YU8GFPEUzSrQgStM5erm12UL24b3qTbYhV7m0NkLpx-RT5YPbp2OouhL3yITs61yGscQqWIg_yhnIY6zyh41m2p6jE2f6ZC8Od4He7u9eV4_1-vnhaXWzrie6xLmm2oDhLUiQqiOdVrh1DpgDUNbt5zEhuaCdpNw6yqjjgGUnDXArMdeKLdD1b-8Ux69iU24Gn8D2vQl2LKnRmIgl0ZTs5OVBlnawXTNFP5i4bf7esANXB2ASmN5FE8Cnf8fpkkuq2TdoIWkf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>901641921</pqid></control><display><type>article</type><title>Detecting latent tuberculosis infection during anti-tumour necrosis factor therapy</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>RINGROSE, J. S ; SANCHE, S. E ; TAYLOR-GJEVRE, R. M</creator><creatorcontrib>RINGROSE, J. S ; SANCHE, S. E ; TAYLOR-GJEVRE, R. M</creatorcontrib><description>There is little information regarding the reliability of repeat tuberculin skin tests (TSTs) and interferon gamma release assays (IGRAs) in detecting latent tuberculosis infection (LTBI) in people on anti-tumour necrosis factor (TNF) medication.
We conducted a prospective, observational study of patients referred to the Saskatoon Tuberculosis (TB) Clinic prior to starting anti-TNF medication. A chest x-ray (CXR), 2-step TST and IGRA (QuantiFERON-TB Gold In-Tube Method) were performed at baseline. Those patients with a baseline TST ≥10 mm and/or a positive IGRA were followed with a clinic visit, CXR, TST and IGRA at 3 and 6 months after starting anti-TNF medication.
Of 106 potential patients, 91 consented to participate. Twenty-six patients had a positive (≥ 10 mm) TST or IGRA at baseline; twelve started and stayed on anti-TNF medication through the 6-month follow-up and completed both planned follow-up visits. The baseline mean TST measurement for the 12 participants was 13.9 mm (SD 11.4), increasing to a mean of 16.8 mm (SD 9.3) post-booster. At 3 months post-anti-TNF initiation, there was an overall decrease in TST measurement (mean=10.0 mm; SD 9.3; p=0.013), with measurements <5 mm in 3 of the 12 patients. By the 6-month TST, a response recovery was observed with a mean TST measurement of 14.5 mm (SD 7.7), with 11/12 ≥5 mm. The IGRA was unchanged throughout the study period in all patients. The overall agreement between TST and IGRA was poor (kappa coefficient = 0.180, p=0.020).
We demonstrated a transient but significant decrease in TST response in the first six months of anti-TNF therapy.</description><identifier>ISSN: 0392-856X</identifier><identifier>EISSN: 1593-098X</identifier><identifier>PMID: 21961892</identifier><language>eng</language><publisher>Pisa: Clinical and Experimental Rheumatology</publisher><subject>Adalimumab ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antirheumatic Agents - therapeutic use ; Bacterial diseases ; Biological and medical sciences ; Diseases of the osteoarticular system ; Etanercept ; Female ; Human bacterial diseases ; Humans ; Immunoglobulin G - therapeutic use ; Infectious diseases ; Infliximab ; Latent Tuberculosis - complications ; Latent Tuberculosis - diagnosis ; Male ; Medical sciences ; Middle Aged ; Prospective Studies ; Radiography, Thoracic - standards ; Receptors, Tumor Necrosis Factor - therapeutic use ; Reproducibility of Results ; Rheumatic Diseases - complications ; Rheumatic Diseases - drug therapy ; Tuberculin Test - standards ; Tuberculosis and atypical mycobacterial infections ; Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><ispartof>Clinical and experimental rheumatology, 2011-09, Vol.29 (5), p.790-794</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25245729$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21961892$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RINGROSE, J. S</creatorcontrib><creatorcontrib>SANCHE, S. E</creatorcontrib><creatorcontrib>TAYLOR-GJEVRE, R. M</creatorcontrib><title>Detecting latent tuberculosis infection during anti-tumour necrosis factor therapy</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>There is little information regarding the reliability of repeat tuberculin skin tests (TSTs) and interferon gamma release assays (IGRAs) in detecting latent tuberculosis infection (LTBI) in people on anti-tumour necrosis factor (TNF) medication.
We conducted a prospective, observational study of patients referred to the Saskatoon Tuberculosis (TB) Clinic prior to starting anti-TNF medication. A chest x-ray (CXR), 2-step TST and IGRA (QuantiFERON-TB Gold In-Tube Method) were performed at baseline. Those patients with a baseline TST ≥10 mm and/or a positive IGRA were followed with a clinic visit, CXR, TST and IGRA at 3 and 6 months after starting anti-TNF medication.
Of 106 potential patients, 91 consented to participate. Twenty-six patients had a positive (≥ 10 mm) TST or IGRA at baseline; twelve started and stayed on anti-TNF medication through the 6-month follow-up and completed both planned follow-up visits. The baseline mean TST measurement for the 12 participants was 13.9 mm (SD 11.4), increasing to a mean of 16.8 mm (SD 9.3) post-booster. At 3 months post-anti-TNF initiation, there was an overall decrease in TST measurement (mean=10.0 mm; SD 9.3; p=0.013), with measurements <5 mm in 3 of the 12 patients. By the 6-month TST, a response recovery was observed with a mean TST measurement of 14.5 mm (SD 7.7), with 11/12 ≥5 mm. The IGRA was unchanged throughout the study period in all patients. The overall agreement between TST and IGRA was poor (kappa coefficient = 0.180, p=0.020).
We demonstrated a transient but significant decrease in TST response in the first six months of anti-TNF therapy.</description><subject>Adalimumab</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Diseases of the osteoarticular system</subject><subject>Etanercept</subject><subject>Female</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Infectious diseases</subject><subject>Infliximab</subject><subject>Latent Tuberculosis - complications</subject><subject>Latent Tuberculosis - diagnosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Radiography, Thoracic - standards</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>Reproducibility of Results</subject><subject>Rheumatic Diseases - complications</subject><subject>Rheumatic Diseases - drug therapy</subject><subject>Tuberculin Test - standards</subject><subject>Tuberculosis and atypical mycobacterial infections</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>0392-856X</issn><issn>1593-098X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0EtLAzEUBeAgiq3VvyCzEVcDeTSvpdQnFARR6G7I3Ek0MpMZ81j039tqxdVdnI_D4R6hOeGa1VirzTGaY6ZprbjYzNBZSp8YU8GFPEUzSrQgStM5erm12UL24b3qTbYhV7m0NkLpx-RT5YPbp2OouhL3yITs61yGscQqWIg_yhnIY6zyh41m2p6jE2f6ZC8Od4He7u9eV4_1-vnhaXWzrie6xLmm2oDhLUiQqiOdVrh1DpgDUNbt5zEhuaCdpNw6yqjjgGUnDXArMdeKLdD1b-8Ux69iU24Gn8D2vQl2LKnRmIgl0ZTs5OVBlnawXTNFP5i4bf7esANXB2ASmN5FE8Cnf8fpkkuq2TdoIWkf</recordid><startdate>20110901</startdate><enddate>20110901</enddate><creator>RINGROSE, J. S</creator><creator>SANCHE, S. E</creator><creator>TAYLOR-GJEVRE, R. M</creator><general>Clinical and Experimental Rheumatology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20110901</creationdate><title>Detecting latent tuberculosis infection during anti-tumour necrosis factor therapy</title><author>RINGROSE, J. S ; SANCHE, S. E ; TAYLOR-GJEVRE, R. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p240t-29aca5bc7c78d1d980bffc3fcc8ef9618367562d725ef232f5c07d7ac5e705983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adalimumab</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Diseases of the osteoarticular system</topic><topic>Etanercept</topic><topic>Female</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Infectious diseases</topic><topic>Infliximab</topic><topic>Latent Tuberculosis - complications</topic><topic>Latent Tuberculosis - diagnosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Radiography, Thoracic - standards</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>Reproducibility of Results</topic><topic>Rheumatic Diseases - complications</topic><topic>Rheumatic Diseases - drug therapy</topic><topic>Tuberculin Test - standards</topic><topic>Tuberculosis and atypical mycobacterial infections</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RINGROSE, J. S</creatorcontrib><creatorcontrib>SANCHE, S. E</creatorcontrib><creatorcontrib>TAYLOR-GJEVRE, R. M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RINGROSE, J. S</au><au>SANCHE, S. E</au><au>TAYLOR-GJEVRE, R. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Detecting latent tuberculosis infection during anti-tumour necrosis factor therapy</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2011-09-01</date><risdate>2011</risdate><volume>29</volume><issue>5</issue><spage>790</spage><epage>794</epage><pages>790-794</pages><issn>0392-856X</issn><eissn>1593-098X</eissn><abstract>There is little information regarding the reliability of repeat tuberculin skin tests (TSTs) and interferon gamma release assays (IGRAs) in detecting latent tuberculosis infection (LTBI) in people on anti-tumour necrosis factor (TNF) medication.
We conducted a prospective, observational study of patients referred to the Saskatoon Tuberculosis (TB) Clinic prior to starting anti-TNF medication. A chest x-ray (CXR), 2-step TST and IGRA (QuantiFERON-TB Gold In-Tube Method) were performed at baseline. Those patients with a baseline TST ≥10 mm and/or a positive IGRA were followed with a clinic visit, CXR, TST and IGRA at 3 and 6 months after starting anti-TNF medication.
Of 106 potential patients, 91 consented to participate. Twenty-six patients had a positive (≥ 10 mm) TST or IGRA at baseline; twelve started and stayed on anti-TNF medication through the 6-month follow-up and completed both planned follow-up visits. The baseline mean TST measurement for the 12 participants was 13.9 mm (SD 11.4), increasing to a mean of 16.8 mm (SD 9.3) post-booster. At 3 months post-anti-TNF initiation, there was an overall decrease in TST measurement (mean=10.0 mm; SD 9.3; p=0.013), with measurements <5 mm in 3 of the 12 patients. By the 6-month TST, a response recovery was observed with a mean TST measurement of 14.5 mm (SD 7.7), with 11/12 ≥5 mm. The IGRA was unchanged throughout the study period in all patients. The overall agreement between TST and IGRA was poor (kappa coefficient = 0.180, p=0.020).
We demonstrated a transient but significant decrease in TST response in the first six months of anti-TNF therapy.</abstract><cop>Pisa</cop><pub>Clinical and Experimental Rheumatology</pub><pmid>21961892</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0392-856X |
| ispartof | Clinical and experimental rheumatology, 2011-09, Vol.29 (5), p.790-794 |
| issn | 0392-856X 1593-098X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_901641921 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adalimumab Adult Aged Aged, 80 and over Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use Bacterial diseases Biological and medical sciences Diseases of the osteoarticular system Etanercept Female Human bacterial diseases Humans Immunoglobulin G - therapeutic use Infectious diseases Infliximab Latent Tuberculosis - complications Latent Tuberculosis - diagnosis Male Medical sciences Middle Aged Prospective Studies Radiography, Thoracic - standards Receptors, Tumor Necrosis Factor - therapeutic use Reproducibility of Results Rheumatic Diseases - complications Rheumatic Diseases - drug therapy Tuberculin Test - standards Tuberculosis and atypical mycobacterial infections Tumor Necrosis Factor-alpha - antagonists & inhibitors |
| title | Detecting latent tuberculosis infection during anti-tumour necrosis factor therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T23%3A46%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Detecting%20latent%20tuberculosis%20infection%20during%20anti-tumour%20necrosis%20factor%20therapy&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=RINGROSE,%20J.%20S&rft.date=2011-09-01&rft.volume=29&rft.issue=5&rft.spage=790&rft.epage=794&rft.pages=790-794&rft.issn=0392-856X&rft.eissn=1593-098X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E901641921%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=901641921&rft_id=info:pmid/21961892&rfr_iscdi=true |